ASP-3291(ASP-3291) - 药物靶点：melanocortin receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ASP 3291、ASP3291

靶点

melanocortin receptor

作用机制

melanocortin receptor激动剂(黑皮质素受体激动剂)

治疗领域

免疫系统疾病消化系统疾病

在研适应症-

非在研适应症

溃疡性结肠炎活动性重度溃疡性结肠炎

原研机构

Astellas Pharma, Inc.

在研机构-

非在研机构

Astellas Pharma, Inc.Telsar Pharma, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 ASP-3291 相关的临床试验

NCT01612039 / Completed临床2期

A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis

This is a Phase 2, randomized, double-blind, multicenter, parallel, placebo controlled study. Approximately 120 eligible patients with mild-to-moderate active ulcerative colitis will be randomized to double blind treatment of either 1,000 mg twice daily (b.i.d.) ASP3291 (2,000 mg/d) or matching placebo in a 1:1 ratio for 8 weeks.
The study hypothesis is that treatment with ASP3291 compared to placebo will improve a patient's ulcerative colitis endoscopic score from baseline to Week 8.

开始日期2012-07-01

申办/合作机构

Telsar Pharma, Inc.

NCT01320332 / Completed临床1期

A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Ulcerative Colitis

The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.

开始日期2010-08-01

申办/合作机构

Telsar Pharma, Inc.

100 项与 ASP-3291 相关的临床结果

登录后查看更多信息

100 项与 ASP-3291 相关的转化医学

登录后查看更多信息

100 项与 ASP-3291 相关的专利（医药）

登录后查看更多信息

100 项与 ASP-3291 相关的药物交易

登录后查看更多信息